MBOT — Microbot Medical Inc.

Is MBOT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Strong Oversold As of October 3, 2026

Microbot Medical Inc. (MBOT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $1.16. The rating moved from Oversold to Strong Oversold on September 30, 2026.

See all oversold Healthcare stocks →

AI analysis

Microbot Medical Inc. shows characteristics of an early‑stage med‑tech issuer: valuation tied to future clinical and commercial milestones, limited visible revenue, and probable near‑term financing needs. Current market risk‑off sentiment and a cooling healthcare/device capital window increase the likelihood of financing challenges and short‑term volatility. Upside depends on clear clinical/regulatory progress or a strategic partnership; downside is driven by cash runway issues, trial/regulatory setbacks, reimbursement uncertainty, and low liquidity.

Key factors

  • Early-stage medical device company with limited or no meaningful commercial revenue to date, implying reliance on clinical progress and partner deals for value creation.
  • Likely constrained cash runway and negative operating cash flow, increasing probability of near-term financing or dilution absent material milestone-driven financing.
  • Small‑cap status and low liquidity make the stock sensitive to broad market risk‑off moves and headline-driven volatility (current market tone is cautious).
  • Novel technology/platform exposure provides asymmetric upside if clinical/regulatory milestones or strategic partnerships are achieved.
  • Sector headwinds: cooling IPO window and risk aversion for consumer-facing and device offerings reduce near-term capital market options and appetite from new investors.
  • Limited publicly available recent disclosures and social/research coverage, which increases information asymmetry and contributes to uncertain near-term sentiment.

Risks

  • Financing and dilution risk if cash runway is short or capital markets remain dislocated.
  • Clinical trial delays, negative outcomes, or regulatory setbacks that could significantly reduce valuation.
  • Reimbursement and payer risk that could limit commercial adoption even if the device is approved.
  • Competition from larger, well-capitalized med‑tech firms and alternative therapeutic approaches.
  • Supply‑chain disruptions and manufacturing scale challenges for complex device components.
  • Low trading liquidity and episodic volume spikes that can amplify downside on negative news.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MBOT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.